Johns Hopkins RNA Innovation Center appoints Michelle Kim as the inaugural Managing Director in collaboration with TriLink BioTechnologies, part of Maravai LifeSciences.
| BioBuzz’s mission is simple: to be more connected. Our regionally-focused storytelling, programs, events and experiences connect, amplify and create impact across the life science workforce in growing biohubs. Submit your People On The Move (free and ongoing) to showcase your company’s growth by promoting your new hires and recent promotions. |
Johns Hopkins RNA Innovation Center’s goal is to accelerate groundbreaking research in RNA therapeutics by sharing our collective expertise and technology with the scientific community. Through the RNA Innovation Center, Michelle Kim will help enable researchers to develop RNA medicines and discover novel clinical applications that can improve human health.
An alumna of The Johns Hopkins University School of Medicine, Michelle brings a wealth of knowledge in RNA biology as well as product development and commercialization in the genomics and long-read sequencing space. Her experiences in academia and industry are going to help the RNA Innovation Center translate important Hopkins discoveries into novel RNA therapeutics.
About Michelle Kim
Kim has worked within the sciences for several years, having several years of combined experience as a lead scientist at Circulomics, Inc., a senior staff scientist at Pacific BioSciences, and a research associate at Howard Hughes Medical Institute. Kim also holds a Ph.D in Biochemistry, Molecular, and Cellular Biology from Johns Hopkins University; the return to her alum university not only showcases the brilliance the institution holds but also the expertise within.
About John Hopkins RNA Innovation Center
Johns Hopkins University established the RNA Innovation Center in collaboration with TriLink Biotechnologies® to accelerate groundbreaking research in RNA therapeutics. The Center was established in 2024 and is housed in the Whiting School of Engineering at the Institute for NanoBioTechnology (INBT). The INBT is comprised of multidisciplinary faculty whose research spans molecular biology, medicine, engineering, and nanoscience, providing an ideal milieu for the exploration of novel RNA therapeutics. The partnership with TriLink affords the Center access to CleanScriptTM, their proprietary state-of-the-art RNA synthesis technology, as well as their technical and cGMP manufacturing expertise. Through the synergy of these academic and commercial pillars, the RNA Innovation Center endeavors to empower investigators to move seamlessly from concept, through discovery, and finally to the cusp of human clinical studies.
